GO
Loading...

Merck & Co Inc

More

  • ACC: Can It "Enhance" Merck And Schering-Plough? Wednesday, 19 Mar 2008 | 2:54 PM ET

    The American College of Cardiology held a telephone press briefing this afternoon to help get reporters up to speed on potential headline-grabbing studies that researchers will present at the annual ACC meeting in Chicago at the end of this month.

  • Merck And Big Pharma: Both Getting A Stock "Booster" Shot? Wednesday, 19 Mar 2008 | 11:14 AM ET
    Gardasil

    Merck this morning announced that it has filed for Food and Drug Administration approval of its blockbuster cervical cancer vaccine, Gardasil, for women 27-45 years old. Right now it's approved for females 9-26.

  • The 'Real Banks' Monday, 17 Mar 2008 | 7:48 PM ET

    To call yourself one, you need cash. And these companies have it.

  • Dow Closes Higher as Investors Cheer Fed Monday, 17 Mar 2008 | 5:01 PM ET

    Enthusiasm for the Federal Reserve's actions to stem the credit crunch propelled the Dow Jones Industrial Average to a higher close Monday, a day when everyone expected a rout due to weekend fire sale of Bear Stearns.

  • JP Morgan's Bargain, Fed Actions Help Stocks Monday, 17 Mar 2008 | 3:35 PM ET

    The Dow Jones Industrial Average pared its losses Monday as the sell-off spurred by the fire sale of Bear Stearns wasn't as bad as expected.

  • Dow Pares Losses; Lehman Plunges Monday, 17 Mar 2008 | 11:40 AM ET

    Stocks plunged at the opening bell Monday as investors were spooked by the cash crisis at Bear Stearns that forced its sale for $2 a share to JP Morgan Chase.

  • The Return of Big Pharma Friday, 14 Mar 2008 | 6:44 PM ET

    This could be the sector to own by next fall's presidential election.

  • Buy This Bottom Tuesday, 4 Mar 2008 | 6:26 PM ET

    There are too many opportunities for investors to be sitting on the sidelines.

  • Merck, SGP's "Enhance" Study No "Late Breaker" At ACC Thursday, 21 Feb 2008 | 4:36 PM ET

    The results of the controversial study called "Enhance" of the cholesterol drug Vytorin from Merck and Schering-Plough will not be presented as a prestigious "late breaker" at the upcoming annual meeting of the American College of Cardiology.

  • Coffee, Me And A Not So "Sweet" Splenda? Thursday, 21 Feb 2008 | 8:37 AM ET
    Splenda

    How much coffee can one woman drink? Watch me. I never drank coffee until I started covering the O.J. Simpson trial (come to think of it, I never drank much alcohol before then, either).

  • Surprise Friday Friday, 15 Feb 2008 | 6:57 PM ET

    A top industry insider gives us the dish on a story of the week. Get the details now!

  • Genentech, JNJ, Pfizer: Big Days Ahead For Pharma Friday, 15 Feb 2008 | 9:41 AM ET

    Taking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.

  • Your First Move For Thursday Feb. 14th Wednesday, 13 Feb 2008 | 7:18 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Winning Streak Continues Wednesday, 13 Feb 2008 | 6:56 PM ET

    Stocks rose for their third consecutive gain to complete their longest winning streak of the year so far on strength in oil, tech and other familiar trends. Also, breaking biotech news on Genentech and Biogen in the Word on the Street.

  • Oil Rallied the Market, Not Retail Wednesday, 13 Feb 2008 | 6:43 PM ET

    And the gains won't last long, Cramer says. Here's how you profit.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • One-on-One with Schering-Plough CEO Fred Hassan Wednesday, 13 Feb 2008 | 11:05 AM ET

    In a CNBC and Mad Money exclusive, Cramer sat down with Schering-Plough CEO Fred Hassan for his first interview since the controversy over the effectiveness of the cholesterol drug Vytorin. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks Close Mixed as Buffett Rally Fades Tuesday, 12 Feb 2008 | 4:54 PM ET

    Stocks closed mixed  Tuesday after an earlier rally inspired by Warren Buffett swooping into the situation with bond insurers and banks teaming up to stop foreclosures.

  • Most Dow Stocks Up After Buffett 'Band-Aid' Tuesday, 12 Feb 2008 | 2:46 PM ET

    Most of the 30 stocks in the Dow were higher Tuesday after billionaire investor Warren Buffett offered a reinsurance plan to troubled bond insurers and top mortgage lenders unveiled a plan aimed at freezing foreclosures.

  • Most Dow Stocks Up After Buffett 'Band-Aid' Tuesday, 12 Feb 2008 | 12:20 PM ET

    Most of the 30 stocks in the Dow were higher Tuesday after billionaire investor Warren Buffett offered a reinsurance plan to troubled bond insurers and top mortgage lenders unveiled a plan aimed at freezing foreclosures.

  • Schering-Plough is bringing up the rear of big pharma earnings season this morning--it reported later than normal because it apparently took longer to do all the accounting for a big acquisition--with a beat on the top and bottom line. But investors, as is usually the case, are more concerned about guidance.